AI is a viable alternative to high throughput screening: a 318-target study
2024 · Scientific Reports · 114 citations
https://doi.org/10.1038/s41598-024-54655-z
A
Audrey Colomba
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
16
Papers
496
Citations
11
h-index
11
i10-index
Audrey Colomba is an academic researcher from University College London. The author has contributed to research in topics: Protein Kinase Regulation and GTPase Signaling & HER2/EGFR in Cancer Research & Lymphoma Diagnosis and Treatment. The author has an h-index of 11, co-authored 14 publications.
ORCID: 0000-0002-5612-8519Papers by this author
worksInhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
2018 · eLife · 72 citations
https://doi.org/10.7554/elife.32271
A small molecule inhibitor of HER3: a proof-of-concept study
2020 · Biochemical Journal · 13 citations
https://doi.org/10.1042/bcj20200496
Targeting the HER3 pseudokinase domain with small molecule inhibitors
2022 · Methods in enzymology on CD-ROM/Methods in enzymology · 3 citations
https://doi.org/10.1016/bs.mie.2022.03.044
Author Correction: AI is a viable alternative to high throughput screening: a 318-target study
2024 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-024-70321-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat